Iron overload cardiomyopathy

Area of Science:

• Cardiology
• Hematology
• Toxicology

Background:

• Iron overload cardiomyopathy (IOC) is a major cause of death in hereditary hemochromatosis and transfusion-dependent anemias.
• Excess iron overwhelms binding capacity, creating toxic non-transferrin-bound iron that damages heart cells.

Purpose of the Study:

• To provide a comprehensive, evidence-based review of the pathophysiology, diagnosis, and management of iron overload cardiomyopathy.
• To highlight recent advancements in treatment strategies and emerging curative therapies.

Main Methods:

• Review of current literature on iron metabolism, cardiac pathophysiology, diagnostic tools, and therapeutic interventions for IOC.
• Analysis of evidence supporting phlebotomy, iron chelation therapy, and adjunctive treatments.

Main Results:

• Cardiac MRI T2* is crucial for diagnosing IOC and guiding treatment, significantly reducing cardiac mortality.
• Phlebotomy is standard for primary hemochromatosis; iron chelators (deferoxamine, deferiprone, deferasirox) are used for transfusion-dependent patients.
• Emerging therapies for underlying conditions like thalassemia may address the root cause of iron loading.

Conclusions:

• IOC requires prompt diagnosis and management to prevent heart failure and arrhythmias.
• Multifaceted treatment approaches, including chelation and addressing the cause of iron overload, are essential for improving patient survival and quality of life.